The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).
Patients with metastatic RCC and a BMI of 25 or greater had significantly longer overall survival compared with patients with a BMI of less than 25, according to the results of a recent study.
The combination of bevacizumab and everolimus had efficacy in patients with unclassified non–clear cell renal cell carcinoma characterized by papillary features, resulting in an objective response rate of 43%.
Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.
Patients with kidney cancer who are considered to be in poor functional health were less likely to receive cancer-directed surgery to treat their disease.
Certain patients with metastatic renal cell carcinoma safely underwent active surveillance of their disease prior to undergoing systemic therapy.
Undergoing complete metastasectomy for metastatic renal cell carcinoma was associated with improved survival outcomes, according to the results of a meta-analysis.
A new study has found a series of potential microRNA biomarkers that could predict tyrosine kinase inhibitor response in RCC patients.
Both African-American and Caucasian patients with advanced RCC have seen improved survival with targeted therapies, though African-Americans still experience survival disadvantages.
Despite improved understanding of the molecular features of renal tumors, increasing expertise in surgical management of localized renal cancers, and multiple effective systemic therapies for metastatic cancer, mortality from renal cell carcinoma remains largely unchanged.